CATO completed the merger with Pharm-Olam.

CATO, a provider of specialized clinical research solutions and a drug development company, completed the merger with Pharm-Olam, a clinical research organization that delivers right-sized trial services to pharmaceutical, biotechnology, government, and public health organizations. Financial terms were not disclosed. “Coming together with CATO SMS is the next step toward achieving our mission of being one of the most trusted clinical research providers in the industry. Both companies share a passion for understanding the distinct needs of our biopharmaceutical clients and customizing our teams and solutions to enable them to deliver innovative therapies to the patients who need them,” Rob Davie, Pharm-Olam CEO.